Blueprint Medicines - BPMC Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $91.57
Forecasted Upside: -1.54%
Number of Analysts: 14
Breakdown:
3 Sell Ratings
2 Hold Ratings
8 Buy Ratings
1 Strong Buy Ratings

^$93.00 As of 04/26/2024 01:00 AM ET

▲ +2.27 (2.50%)

1 month | 3 months | 12 months

Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

^$91.57

▼ -1.54% Downside Potential

This price target is based on 14 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $91.57, with a high forecast of $130.00 and a low forecast of $43.00. The average price target represents a -1.54% upside from the last price of $93.00.

Current Consensus is Moderate Buy

The current consensus among 14 contributing investment analysts is to moderate buy stock in Blueprint Medicines. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

11/5/2022

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

2/3/2023

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

5/4/2023

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

8/2/2023

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

10/31/2023

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

1/29/2024

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

3/29/2024

1 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

4/28/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/26/2024	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$120.00 ➝ $130.00	Low
4/26/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$110.00	Low
4/26/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$97.00	Low
4/26/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$125.00	Low
4/10/2024	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$114.00	Low
2/26/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$97.00	Low
2/16/2024	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$114.00	Low
2/16/2024	Citigroup	Boost Target	Sell ➝ Sell	$54.00 ➝ $65.00	Low
2/13/2024	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$58.00 ➝ $70.00	Low
2/5/2024	Wedbush	Reiterated Rating	Outperform	$97.00	Low
1/16/2024	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$114.00	Low
1/9/2024	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$95.00 ➝ $97.00	Low
1/8/2024	Wedbush	Reiterated Rating	Outperform	$100.00 ➝ $97.00	Low
12/22/2023	Raymond James	Boost Target	Strong-Buy ➝ Strong-Buy	$85.00 ➝ $100.00	Low
12/19/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$86.00 ➝ $115.00	Low
12/11/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$85.00	Low
11/10/2023	Wedbush	Reiterated Rating	Outperform	$80.00	Low
10/27/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$59.00 ➝ $63.00	Low
10/27/2023	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$85.00	Low
10/27/2023	Needham & Company LLC	Boost Target	Buy ➝ Buy	$66.00 ➝ $74.00	Low
10/27/2023	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$46.00 ➝ $58.00	Low
8/21/2023	Needham & Company LLC	Boost Target	Buy ➝ Buy	$65.00 ➝ $66.00	Low
8/7/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$114.00	Low
8/3/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $59.00	Low
8/3/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$93.00 ➝ $83.00	Low
8/3/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$85.00	Low
8/2/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$65.00	Low
7/31/2023	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $82.00	Low
7/14/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$55.00	Low
6/14/2023	Wells Fargo & Company	Boost Target		$48.00 ➝ $55.00	Low
6/5/2023	SVB Leerink	Downgrade	Market Perform ➝ Underperform		Low
6/5/2023	SVB Securities	Downgrade	Market Perform ➝ Underperform	$48.00 ➝ $43.00	Low
5/23/2023	Guggenheim	Boost Target		$78.00 ➝ $82.00	Low
5/23/2023	HC Wainwright	Boost Target		$75.00 ➝ $85.00	Low
5/23/2023	Barclays	Boost Target		$44.00 ➝ $46.00	Low
5/5/2023	VNET Group	Reiterated Rating	Maintains		Low
5/5/2023	HC Wainwright	Boost Target		$70.00 ➝ $75.00	Low
4/19/2023	Needham & Company LLC	Reiterated Rating	Buy	$57.00	Low
3/30/2023	JMP Securities	Reiterated Rating	Market Outperform	$114.00	Low
3/21/2023	Stifel Nicolaus	Boost Target		$80.00 ➝ $84.00	Low
2/28/2023	JMP Securities	Reiterated Rating	Market Perform	$114.00	Low
2/28/2023	HC Wainwright	Reiterated Rating	Buy	$70.00	Low
2/28/2023	Needham & Company LLC	Reiterated Rating	Buy	$57.00	Low
2/24/2023	SVB Securities	Lower Target		$45.00 ➝ $38.00	Low
2/24/2023	SVB Leerink	Lower Target	Market Perform	$45.00 ➝ $38.00	Low
2/17/2023	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $57.00	N/A
2/17/2023	HC Wainwright	Reiterated Rating	Buy	$70.00	N/A
2/17/2023	Raymond James	Lower Target	Strong-Buy	$115.00 ➝ $85.00	N/A
2/10/2023	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
1/27/2023	Morgan Stanley	Lower Target	Equal Weight	$75.00 ➝ $50.00	Low
1/23/2023	Barclays	Lower Target	Equal Weight	$50.00 ➝ $44.00	Low
1/2/2023	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$41.00	Low
12/14/2022	Needham & Company LLC	Initiated Coverage	Buy	$60.00	Low
12/12/2022	Barclays	Lower Target	Equal Weight	$58.00 ➝ $53.00	Low
11/4/2022	JMP Securities	Lower Target	Market Outperform	$152.00 ➝ $114.00	Low
11/3/2022	The Goldman Sachs Group	Lower Target	Buy	$143.00 ➝ $108.00	Low
11/2/2022	Jefferies Financial Group	Lower Target		$84.00 ➝ $80.00	Low
11/2/2022	SVB Leerink	Lower Target	Market Perform	$57.00 ➝ $52.00	Low
11/2/2022	Morgan Stanley	Lower Target	Equal Weight	$80.00 ➝ $75.00	Low
11/2/2022	Barclays	Lower Target	Equal Weight	$70.00 ➝ $58.00	Low
11/2/2022	Wedbush	Lower Target	Outperform	$120.00 ➝ $106.00	Low
11/2/2022	HC Wainwright	Lower Target	Buy	$80.00 ➝ $70.00	N/A
11/2/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
9/14/2022	Berenberg Bank	Initiated Coverage	Buy	$90.00	Low
9/9/2022	Morgan Stanley	Boost Target	Equal Weight	$65.00 ➝ $80.00	Low
9/7/2022	Credit Suisse Group	Boost Target		$80.00 ➝ $90.00	Low
9/6/2022	Oppenheimer	Boost Target	Outperform	$80.00 ➝ $90.00	Low
8/22/2022	Jefferies Financial Group	Boost Target	Buy	$78.00 ➝ $84.00	Low
8/18/2022	SVB Leerink	Lower Target	Market Perform ➝ Market Perform	$65.00 ➝ $57.00	Low
8/18/2022	Stifel Nicolaus	Boost Target	Buy	$93.00 ➝ $100.00	Low
8/17/2022	HC Wainwright	Lower Target	Buy	$100.00 ➝ $80.00	Low
8/3/2022	Raymond James	Lower Target	Strong-Buy	$133.00 ➝ $115.00	Low
8/3/2022	HC Wainwright	Reiterated Rating	Buy		Low
8/3/2022	The Goldman Sachs Group	Boost Target	Buy	$126.00 ➝ $143.00	Low
8/3/2022	SVB Leerink	Boost Target	Market Perform	$56.00 ➝ $65.00	Low
8/2/2022	Piper Sandler	Lower Target		$65.00 ➝ $59.00	Low
7/7/2022	Oppenheimer	Initiated Coverage	Outperform	$80.00	N/A
7/1/2022	Stifel Nicolaus	Lower Target		$98.00 ➝ $90.00	Low
7/1/2022	SVB Leerink	Lower Target	Market Perform	$60.00 ➝ $56.00	Low
6/27/2022	Wells Fargo & Company	Initiated Coverage	Underweight	$40.00	Low
6/14/2022	Morgan Stanley	Lower Target	Equal Weight	$92.00 ➝ $65.00	Low
6/13/2022	SVB Leerink	Lower Target	Market Perform	$82.00 ➝ $60.00	Low
6/10/2022	HC Wainwright	Reiterated Rating	Buy	$100.00	High
6/9/2022	Citigroup	Downgrade	Neutral ➝ Sell	$68.00 ➝ $41.00	High
6/9/2022	JMP Securities	Reiterated Rating	Buy	$152.00	High
6/1/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$88.00 ➝ $78.00	High
5/18/2022	Piper Sandler	Lower Target	Neutral	$84.00 ➝ $65.00	High
5/4/2022	Robert W. Baird	Lower Target		$123.00 ➝ $96.00	Medium
4/13/2022	Citigroup	Lower Target	Neutral	$71.00 ➝ $68.00	High
4/11/2022	JMP Securities	Reiterated Rating	Buy	$152.00	Medium
3/4/2022	Stifel Nicolaus	Boost Target	Buy	$100.00 ➝ $105.00	Medium
2/28/2022	Wedbush	Reiterated Rating	Outperform	$126.00	Low
2/28/2022	Citigroup	Initiated Coverage	Neutral	$71.00	Low
2/17/2022	SVB Leerink	Lower Target	Outperform ➝ Market Perform	$93.00 ➝ $82.00	High
2/17/2022	HC Wainwright	Lower Target	Buy	$135.00 ➝ $100.00	High
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$111.00 ➝ $92.00	Medium
1/24/2022	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$120.00 ➝ $95.00	Low
1/12/2022	SVB Leerink	Lower Target	Outperform	$132.00 ➝ $120.00	High
1/3/2022	Guggenheim	Boost Target		$120.00 ➝ $122.00	High
11/30/2021	HC Wainwright	Reiterated Rating	Buy	$134.00	High
11/30/2021	JMP Securities	Reiterated Rating	Buy	$151.00	High
11/10/2021	Raymond James	Boost Target	Strong-Buy	$122.00 ➝ $133.00	Low
10/29/2021	Morgan Stanley	Boost Target	Equal Weight	$96.00 ➝ $111.00	High
7/30/2021	Morgan Stanley	Lower Target	Equal Weight	$101.00 ➝ $96.00	Medium
6/17/2021	Wedbush	Lower Target	Outperform	$136.00 ➝ $130.00	High
6/17/2021	SVB Leerink	Boost Target	Outperform	$127.00 ➝ $137.00	Low
6/17/2021	Robert W. Baird	Boost Target	Outperform	$119.00 ➝ $123.00	High
4/30/2021	Morgan Stanley	Lower Target	Equal Weight	$105.00 ➝ $101.00	High
4/13/2021	Wedbush	Boost Target	Outperform	$119.00 ➝ $136.00	Low
3/30/2021	Credit Suisse Group	Initiated Coverage	Neutral	$100.00	High
2/25/2021	Morgan Stanley	Lower Target	Equal Weight	$112.00 ➝ $105.00	Low
2/18/2021	HC Wainwright	Reiterated Rating	Buy		High
2/18/2021	Barclays	Boost Target	Equal Weight	$90.00 ➝ $95.00	High
1/12/2021	SVB Leerink	Boost Target	Positive ➝ Outperform	$121.00 ➝ $127.00	High
12/18/2020	JMP Securities	Boost Target	Outperform	$118.00 ➝ $152.00	High
12/14/2020	BMO Capital Markets	Boost Target	Outperform	$113.00 ➝ $132.00	Medium
12/2/2020	Stifel Nicolaus	Initiated Coverage	Hold	$110.00	High
11/2/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$90.00 ➝ $96.00	High
11/2/2020	HC Wainwright	Boost Target	Buy	$110.00 ➝ $135.00	High
10/30/2020	Wedbush	Boost Target		$102.00 ➝ $115.00	Low
10/30/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$112.00	Low
10/29/2020	Piper Sandler	Boost Target	Neutral	$77.00 ➝ $81.00	Medium
10/16/2020	Raymond James	Boost Target	Positive ➝ Strong-Buy	$106.00 ➝ $122.00	Medium
10/13/2020	Morgan Stanley	Boost Target	Overweight	$92.00 ➝ $100.00	Low
9/23/2020	SVB Leerink	Boost Target	Outperform	$107.00 ➝ $121.00	Medium
9/23/2020	BMO Capital Markets	Boost Target	Outperform	$105.00 ➝ $113.00	Medium
9/23/2020	Barclays	Boost Target	Equal Weight	$77.00 ➝ $90.00	Medium
9/22/2020	Raymond James	Reiterated Rating	Buy		Medium
9/2/2020	Raymond James	Reiterated Rating	Buy		High
7/31/2020	HC Wainwright	Reiterated Rating	Buy		Low
7/27/2020	SVB Leerink	Boost Target	Outperform	$106.00 ➝ $107.00	Medium
7/15/2020	Morgan Stanley	Boost Target	Overweight	$88.00 ➝ $92.00	Low
7/15/2020	Barclays	Reiterated Rating	Hold ➝ Neutral		High
7/15/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$85.00 ➝ $95.00	Medium
7/15/2020	SVB Leerink	Boost Target	Outperform	$105.00 ➝ $106.00	High
7/15/2020	HC Wainwright	Boost Target	Buy	$66.00 ➝ $110.00	High
7/14/2020	Robert W. Baird	Boost Target	Outperform	$90.00 ➝ $100.00	High
7/14/2020	Raymond James	Boost Target	Positive ➝ Strong-Buy	$95.00 ➝ $106.00	High
6/8/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Positive ➝ Buy	$70.00 ➝ $85.00	High
6/8/2020	BMO Capital Markets	Boost Target	Outperform	$75.00 ➝ $111.00	High
5/7/2020	HC Wainwright	Reiterated Rating	Buy	$66.00	Medium
5/4/2020	Barclays	Initiated Coverage	Equal Weight	$59.00	Low
4/30/2020	Morgan Stanley	Lower Target	Overweight	$103.00 ➝ $88.00	Low
4/29/2020	JMP Securities	Lower Target	Market Outperform	$107.00 ➝ $103.00	Medium
4/29/2020	BMO Capital Markets	Lower Target	Outperform	$89.00 ➝ $75.00	Medium
4/29/2020	SVB Leerink	Lower Target	Outperform	$125.00 ➝ $105.00	Medium
4/29/2020	HC Wainwright	Lower Target	Buy	$100.00 ➝ $66.00	Medium
3/24/2020	Wedbush	Reiterated Rating	Outperform		High
3/17/2020	SVB Leerink	Boost Target	Outperform ➝ Positive	$116.00 ➝ $125.00	Medium
3/17/2020	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$74.00 ➝ $89.00	High
3/16/2020	Cowen	Initiated Coverage	Buy		High
3/16/2020	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$70.00	High
2/18/2020	Morgan Stanley	Lower Target	Overweight	$108.00 ➝ $103.00	Low
2/13/2020	Cowen	Reiterated Rating	Buy		High
1/27/2020	BMO Capital Markets	Initiated Coverage	Market Perform	$74.00	Low
1/15/2020	Wedbush	Reiterated Rating	Positive ➝ Outperform	$141.00 ➝ $122.00	Low
1/10/2020	SVB Leerink	Boost Target		$103.00 ➝ $120.00	Low
1/9/2020	HC Wainwright	Reiterated Rating	Buy		Medium
12/20/2019	Piper Sandler Companies	Lower Target	Neutral	$85.00 ➝ $77.00	Low
12/10/2019	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$75.00 ➝ $70.00	Low
12/2/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Sell		Medium
11/7/2019	HC Wainwright	Reiterated Rating	Buy	$100.00	Low
11/6/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$106.00 ➝ $112.00	Medium
10/28/2019	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$110.00 ➝ $75.00	High
10/22/2019	JMP Securities	Initiated Coverage	Outperform	$106.00	High
10/11/2019	Morgan Stanley	Lower Target	Overweight	$110.00 ➝ $109.00	Low
10/3/2019	HC Wainwright	Initiated Coverage	Buy	$100.00	High
9/30/2019	Cowen	Reiterated Rating	Buy		High
9/12/2019	Raymond James	Upgrade	Market Perform ➝ Outperform		Low
9/9/2019	Piper Sandler Companies	Reiterated Rating	Hold		Low
9/9/2019	Cowen	Reiterated Rating	Buy		High
8/29/2019	Piper Sandler Companies	Initiated Coverage	Neutral	$85.00	Low
8/14/2019	Raymond James	Reiterated Rating	Mkt Perform ➝ Market Perform		High
7/18/2019	Robert W. Baird	Initiated Coverage	Outperform	$120.00	Medium
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$110.00	Medium
6/17/2019	Cowen	Reiterated Rating	Buy		Low
6/2/2019	Cowen	Reiterated Rating	Buy		High
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$125.00	High

(Data available from 4/28/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2023

6 very positive mentions
12 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/31/2023

7 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/30/2023

18 very positive mentions
12 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/30/2023

14 very positive mentions
9 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/29/2024

23 very positive mentions
26 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

2/28/2024

19 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/29/2024

11 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/28/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
19 hours ago
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $130.00
americanbankingnews.com
19 hours ago
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by HC Wainwright
americanbankingnews.com
19 hours ago
Needham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)
americanbankingnews.com
19 hours ago
Wedbush Reiterates "Outperform" Rating for Blueprint Medicines (NASDAQ:BPMC)
finance.yahoo.com
4/26/2024
Rubrik to debut on NYSE, IPO priced at $32 per share

Very Positive

marketbeat.com
4/27/2024
State of New Jersey Common Pension Fund D Sells 13,058 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
markets.businessinsider.com
4/26/2024
Blueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease Treatments
marketbeat.com
4/25/2024
Semanteon Capital Management LP Makes New $1.18 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com
4/22/2024
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Trimmed by Raymond James & Associates
marketbeat.com
4/17/2024
Readystate Asset Management LP Takes $3.69 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $93.00

$90.47

$94.98

50 Day Range

MA: $90.79

$85.18

$99.79

52 Week Range

Now: $93.00

$43.89

$101.00

Volume

725,963 shs

Average Volume

583,126 shs

Market Capitalization

$5.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?: The following Wall Street analysts have issued stock ratings on Blueprint Medicines in the last year: Barclays PLC, Citigroup Inc., Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., VNET Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BPMC.
What is the current price target for Blueprint Medicines?: 14 Wall Street analysts have set twelve-month price targets for Blueprint Medicines in the last year. Their average twelve-month price target is $91.57, suggesting a possible downside of 1.5%. Stifel Nicolaus has the highest price target set, predicting BPMC will reach $130.00 in the next twelve months. SVB Securities has the lowest price target set, forecasting a price of $43.00 for Blueprint Medicines in the next year.
View the latest price targets for BPMC.
What is the current consensus analyst rating for Blueprint Medicines?: Blueprint Medicines currently has 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BPMC.
What other companies compete with Blueprint Medicines?: Other companies that are similar to Blueprint Medicines include Apellis Pharmaceuticals, Ionis Pharmaceuticals, Organon & Co., Elanco Animal Health and Forty Seven. Learn More about companies similar to Blueprint Medicines.
How do I contact Blueprint Medicines' investor relations team?: Blueprint Medicines' physical mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 374-7580 and its investor relations email address is [email protected]. The official website for Blueprint Medicines is www.blueprintmedicines.com. Learn More about contacing Blueprint Medicines investor relations.

Blueprint Medicines - BPMC Stock Price Target and Predictions

Analyst Price Target for BPMC

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.78 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?

What is the current price target for Blueprint Medicines?

What is the current consensus analyst rating for Blueprint Medicines?

What other companies compete with Blueprint Medicines?

How do I contact Blueprint Medicines' investor relations team?